Whalen Wealth Management Inc. Takes Position in Ascendis Pharma A/S $ASND

Whalen Wealth Management Inc. purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,620 shares of the biotechnology company’s stock, valued at approximately $919,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers raised its stake in Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after buying an additional 55 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Ascendis Pharma A/S by 0.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company’s stock valued at $2,103,000 after acquiring an additional 73 shares during the last quarter. Main Management ETF Advisors LLC raised its position in shares of Ascendis Pharma A/S by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,864 shares of the biotechnology company’s stock valued at $1,012,000 after acquiring an additional 96 shares in the last quarter. GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 15.2% during the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 97 shares during the last quarter. Finally, Gilbert & Cook Inc. boosted its holdings in Ascendis Pharma A/S by 2.0% in the second quarter. Gilbert & Cook Inc. now owns 6,750 shares of the biotechnology company’s stock worth $1,165,000 after purchasing an additional 131 shares during the period.

Analyst Ratings Changes

A number of analysts have weighed in on ASND shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, October 8th. Wedbush reissued an “outperform” rating and issued a $220.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday, November 18th. Bank of America lifted their target price on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $256.73.

Ascendis Pharma A/S Stock Down 1.5%

Ascendis Pharma A/S stock opened at $199.80 on Friday. Ascendis Pharma A/S has a 52-week low of $118.03 and a 52-week high of $229.94. The firm has a market capitalization of $12.37 billion, a price-to-earnings ratio of -45.00 and a beta of 0.45. The firm has a 50-day moving average price of $205.99 and a two-hundred day moving average price of $192.41.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. Research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.